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ABSTRACT
Endogenous Cushing’s syndrome (CS) is a rare cause of secondary osteoporosis. The long-term consequences for bone metabolism
after successful surgical treatment remain largely unknown. We assessed bone mineral density and fracture rates in 89 patients with
confirmed Cushing’s syndrome at the time of diagnosis and 2 years after successful tumor resection. We determined five bone turn-
over markers at the time of diagnosis, 1 and 2 years postoperatively. The bone turnover markers osteocalcin, intact procollagen-IN-
propeptide (PINP), alkaline bone phosphatase, CTX-I, and TrAcP 5b were measured in plasma or serum by chemiluminescent immu-
noassays. For comparison, 71 sex-, age-, and body mass index (BMI)-matched patients in whom Cushing’s syndrome had been
excluded were studied. None of the patients received specific osteoanabolic treatment. At time of diagnosis, 69% of the patients
had low bone mass (mean T-score = −1.4  1.1). Two years after successful surgery, the T-score had improved in 78% of patients
(mean T-score 2 years postoperatively −1.0  0.9). The bone formation markers osteocalcin and intact PINP were significantly
decreased at time of diagnosis (p ≤ 0.001 and p = 0.03, respectively), and the bone resorption marker CTX-I and TrAcP 5b increased.
Postoperatively, the bone formation markers showed a three- to fourfold increase 1 year postoperatively, with a moderate decline
thereafter. The bone resorption markers showed a similar but less pronounced course. This study shows that the phase immediately
after surgical remission from endogenous CS is characterized by a high rate of bone turnover resulting in a striking net increase in
bone mineral density in the majority of patients. © 2020 The Authors. Journal of Bone and Mineral Research published by American
Society for Bone and Mineral Research.
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Introduction
Cushing’s syndrome (CS) is a rare disease with approximately0.7 to 2.4 new cases per 1 million per year.(1) Osteoporosis
and osteopenia are typical comorbidities of patients with endog-
enous and exogenous CS. Depending on the study, 60% to 80%
of patients have evidence for a reduced bone mineral density(2)
characteristically affecting the entire skeleton.(3) About 5% of
all cases of secondary osteoporosis are caused by hypercortiso-
lism.(4) However, data from prospective, well-powered studies
are rare, and few risk factors that would predict bone health have
been identified so far. Guidelines for the management of osteo-
porosis due to endogenous CS are still missing.(5) In terms of risk
assessment, the subtype of CS does not seem to influence
osteoporosis risk,(6) whereas the morning cortisol levels are neg-
atively correlated with lumbar bone mineral density.(6) The dura-
tion of endogenous Cushing’s syndrome (or the duration of
exogenous replacement therapy after successful surgery) obvi-
ously affects bone mineral density.(7) Whether the T-score is the
best predictor for fracture risk is not quite clear.(2)
Another area of uncertainty is the natural course of osteoporo-
sis and bone turnover markers once the diagnosis of Cushing’s
syndrome has been established. A number of studies have
addressed this topic, but the interpretation of the results is ham-
pered because of limited patient numbers, concomitant osteoa-
nabolic treatment, or both.(8–10) In-depth insight on bone
remodeling in CS might come from bone turnover marker stud-
ies. For example, the bone formation marker osteocalcin is
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suppressed in untreated CS,(3) a consistent observationmaking it
useful as a diagnostic marker for CS.(2)
Based on the paucity of data, the lack of evidence for treat-
ment guidelines, and the pressing open questions regarding risk
assessment and management of osteoporosis, we performed a
sufficiently powered study to analyze the natural course of bone
turnover and bone mineral density in a monocentric cohort of
patients with endogenous Cushing’s syndrome. To the best of
our knowledge, this is the first such study, and the data obtained




This study was performed as part of the prospective German
Cushing registry, which has included 450 consecutive patients
referred to our department for suspected CS since 2012. Struc-
ture and general characteristics of the registry have been
described in detail previously.(11–14) All patients included in the
registry underwent a standardized biochemical screening and
clinical examination at time of diagnosis and a yearly follow-up
after treatment to treat comorbidities and diagnose recurrence
of the disease early.
In all patients, standard screening for CS with a 1 mg low-dose
overnight dexamethasone suppression test (LDDST), collection
of 24-hour urine (UFC), and sampling of midnight salivary cortisol
were performed. When the diagnosis of CS was confirmed, fur-
ther subtyping was based on plasma adrenocorticotropic hor-
mone (ACTH), corticotropin-releasing hormone (CRH) test,
high-dose dexamethasone suppression test, imaging, and infe-
rior petrosal sinus sampling (in case of ACTH dependence). Final
diagnosis was CS in 156 patients and exclusion of CS in the
remaining 294 patients. Patients with excluded CS were a quite
heterogenic group with lead symptoms such as obesity (73%),
arterial hypertension (50%), or hirsutism (33%). Final diagnoses
in these subjects were metabolic syndrome, polycystic ovary
syndrome (PCOS), obesity, depression, or primary hyperaldoster-
onism. Patient selection is shown in Fig. 1.
In our analysis, we excluded patients for whom no densitom-
etry data were available (n = 63) and patients receiving pharma-
cologic treatment for osteoporosis following diagnosis (n = 4).
Densitometry data were not available for multiple reasons (very
young age, external densitometry in a different clinic, missing
consent to perform densitometry).
We matched the remaining 89 patients with 71 controls sub-
jects selected from those subjects in whom CS was excluded.
Matching was done according to sex, age, and body mass index
(BMI). None of the patients and controls received specific osteoa-
nabolic or antiresorptive treatment, but 47% of patients with CS
received vitamin D supplementation after remission. At time of
diagnosis, 11% of controls and 17% of patients with CS received
vitamin D supplementation.
Methods
In patients with confirmed CS, a bone mineral densitometry was
conducted. Bone mineral density (BMD) was determined at the
lumbar spine and the femur (neck and total femur).
If a reduced bone mineral density was diagnosed, a follow-up
densitometry was performed 2 years after surgery. If bone min-
eral density was normal initially or during follow-up, only one fur-
ther densitometry was performed 2 or 3 years after initial
diagnosis. An improvement or decrease of bone mineral density
was defined according to the least significant change
(LSC = 2.8 × 1.8%).(15) Accordingly, an alteration of more than
5.04% of BMDwas rated as significant. A detailed fracture history
was taken and X-ray of the spine was performed when clinical
suspicion for fractures was high.
In all patients, blood samples (serum and plasma) were taken
at time of diagnosis and also 1 and 2 years after successful trans-
sphenoidal surgery or adrenalectomy. Blood was taken in the
fasting state between 8:00 and 10:00 a.m. Samples were centri-
fuged within 20 minutes at 4C and stored at −80 until assayed.
Three bone formation markers and two bone resorption markers
were measured: osteocalcin, intact procollagen I-N-propeptide
(PINP), and bone alkaline phosphatase (BAP) as bone formation
markers, and CrossLaps (CTX-I) and tartrate-resistant acid phos-
phatase (5b TrAcP5b) as bone resorption marker, on basis of
Fig. 1. Patient selection. *Very young age; patient conducted densitometry in a different clinic/outpatient clinic; patient refused densitometry. CS = Cush-
ing’s syndrome; BMD = bone mineral density; BMI = body mass index. Bold text indicates actual cohort of the study.
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published data demonstrating their usefulness in CS and primary
osteoporosis.(2,16)
Samples were measured at the Endocrine Laboratory of the
Department of Internal Medicine IV on the iSYS automated ana-
lyzer (IDS-iSYS, Boldon, UK) by well-validated assays.(17,18) Pub-
lished, method-specific reference intervals are available from a
large healthy population.(19,20) For the determination of osteocal-
cin, an N-MID assay was used, as pre-analytics are less critical in
this assay.(21) TrAcp 5b is a new marker, which, in contrast to
CTX-1, can also reliably be measured in the non-fasting state.(22)
Statistical analysis
In a priori power analysis, we calculated that a total sample size
of 102 would be sufficient to identify significant differences
between groups, assuming a medium effect size (0.5), a power
of 1 – β = 0.80 and a type I error of α = 0.05, with 51 subjects hav-
ing Cushing’s syndrome and 51 subjects being control subjects
after excluding Cushing’s syndrome.
For statistical analysis, SPSS 25 (IBM Corp., Armonk, NY, USA)
was used. Clinical characteristics are shown as mean and stan-
dard deviation when data is normal distributed; otherwise as
median and ranges. Because of the lack of normal distribution
of bone turnover markers, nonparametric tests were used to test
differences between groups. Differences between bone turnover
markers at different times were tested by Friedman test. Multiple
regression analysis was used to investigate differences between
CS and the control group regarding bone turnover markers
adjusted for sex, age, and BMI. Any p values < 0.05 were consid-
ered to indicate statistical significance.
Results
Patient characteristics
The clinical and biochemical characteristics of the patient sample
are summarized in Table 1. Sixty-five percent of patients had
pituitary CS, 28% adrenal, and 7% suffered from ectopic
CS. Patients and controls were well-matched regarding sex,
age, and vitamin D levels and supplementation, but differed in
terms of diabetes prevalence.
Baseline evaluation
At time of diagnosis, the mean levels of bone formation markers
osteocalcin and intact PINP were significantly decreased compared
with the controls, and the bone formation marker bone alkaline
phosphatase was increased (Table 1; Fig. 2). Both bone degradation
markers CTX and TrAcP were increased (Table 1). Taken together,
this demonstrates increased bone resorption and decreased bone
formation in florid CS. Results of multiple linear regression analysis
comparing Cushing’s syndrome patients and controls are shown
in Table 2. Bone markers were similar in patients with a reduced
bonemass versus thosewith a normal bonemass (data not shown).
Overall, bone mineral density was decreased with an average
lowest T-score of −1.4 (1.1). BMD was significantly lower
(p = 0.001) at the femoral neck (T-score = −0.9  1.0) and the
spine (T-score = −1.0  1.5) compared with the total femur (T-
score = −0.5  1.2). Twenty-eight patients (32%) had a normal
bone mineral density, 46 (52%) osteopenia, and the other
15 patients (17%) osteoporosis with a T-score lower than −2.5.
Seventeen of the patients (19%) had a history of low-trauma oste-
oporotic fractures (9 vertebral fractures, 8 nonvertebral fractures). The
fractures took place shortly before diagnosis (58%) or more than
2 years before diagnosis of the CS (42%). Patients with osteoporotic
fractures had a significantly lower T-score than patients without frac-
tures (T-score = −1.9  0.8 versus −1.3  1.1, p = 0.03) but did not
differ in the values of the bone turnover markers or standard bio-
chemical screening. Subtype, age, or BMI also did not differ between
groups. However,menwere significantly at higher risk of having frac-
tures thanwomen (35% ofmen had fractures versus 14% ofwomen,
p=0.03). Both severity of hypercortisolism andduration of CS did not
contribute to fractures rates (data not shown), but UFC was signifi-
cantly higher in patients with a T-score lower than −1.5 (Table 3).
Table 1. Clinical and Biochemical Baseline Characteristics of Patients with Cushing’s Syndrome (CS) and Control Subjects in Whom CS
Has Been Excluded
CS at time of diagnosis (n = 89) CS excluded (n = 71) p Value
Sex 66 women (74%), 23 men (26%) 53 women (75%), 18 men (25%) 0.94
Age (years) 44  13 43  14 0.56
BMI 30  7 31  6 0.11
Vitamin D (ng/mL) 24  10 24  12 0.59
Vitamin D supplementation 17% 11% 0.37
Diabetes mellitus 30% (26) 11% (7) 0.007
Morning serum cortisol (μg/dL) 18 (11.7–24.9) 8.4 (5.9–11.6) ≤0.001
LDDST (μg/dL) 14.7 (7.7–23.7) 1.0 (0.8–1.2) ≤0.001
UFC (μg/24 h) 587 (331–843) 140 (78–216) ≤0.001
ACTH (pg/mL) 47 (9–76) 13 (9–18) ≤0.001
Late-night salivary cortisol (ng/mL) 7.9 (3.3–11.8) 1.2 (0.6–1.8) ≤0.001
Bone turnover markers
Osteocalcin (ng/mL) 8 (5–13) 13 (10–17) <0.001
PINP (ng/mL) 35 (29–62) 52 (35–73) 0.025
BAP (μg/L) 23 (16–31) 17 (14–24) 0.006
CTX-I (ng/mL) 0.28 (0.17–0.42) 0.23 (0.12–0.32) 0.033
TrAcP (U/L) 2.3 (1.7–3.4) 1.9 (1.3–2.4) 0.009
Date are shown as mean  standard deviation or median and ranges.
BMI = body mass index; LDDST = low-dose dexamethasone suppression test; UFC = urinary free cortisol; ACTH = adrenocorticotropic hormone;
PINP = intact procollagen I-N-propeptide; BAP = bone alkaline phosphatase; CTX-I = CrossLaps; TrAcP = tartrate-resistant acid phosphatase. Bold numbers
indicate statistical significance.
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One- and 2-year follow-up
Surgical tumor resection leading to biochemical remission of CS
resulted in a strong increase of bone formationmarkers tested at
1-year follow-up (Table 4; Fig. 2A, B). After 2 years, the markers
had decreased slightly but remained elevated. Bone resorption
markers were mildly increased at time of diagnosis, increased
further at 1 year post-surgery, and returned almost to normal
levels at 2 years (Table 4; Fig. 2D, E). A follow-up bone densitom-
etry conducted in 40 patients showed a parallel increase of the T-
score of 0.6  0.8 (Fig. 2F). In particular, BMD of the spine
improved (Table 5).
In 78% of patients, bone mineral density improved after
2 years; in 45% of patients, T-score improved more than 0.5. No
clinical fractures occurred after successful treatment of the
CS. There was no significant correlation between improvement
of bone mineral density and any of the bone turnover markers.
Discussion
This study investigated for the first time to our knowledge a panel of
bone formation and resorption markers in a large cohort of patients
with CS over the long term. The unique and comprehensive data
show that initially bone metabolism is characterized by decreased
bone formation and increased bone resorption, in line with the clas-
sical action of glucocorticoids. Successful treatment of endogenous
Cushing’s syndrome leads to a strong activation of bone turnover,
characterized by increased bone formation and bone resorption, a
process that is continuous beyond year 2 after remission of CS,
although at a reduced activity level. In parallel, bone mineral density
increases in the majority of patients. Although 19% had low-trauma
fractures at baseline, none of the subjects experienced clinical frac-
tures during follow-up. In summary, these data give new insight into
bone healing after remission of CS. They strongly suggest that an
Fig. 2. Bone turnover markers and bone mineral density at baseline and 1 and 2 years after remission. Boxplot = median and ranges of bone turnover
marker in patients with Cushing’s syndrome.Gray box =median and ranges of bone turnovermarkers in the control group.PINP = procollagen I-N-propep-
tide; BAP = bone alkaline phosphatase; TrAcP = tartrate-resistant acid phosphatase; CTX-I = CrossLaps.
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observational approach to the bone phenotype is justified as long as
remission from CS is secured.
Reversibility of osteoporosis and bone turnover markers
Although established in osteoporosis research, bone turnover
markers are not measured on a routine basis in patients with
CS. However, it is a consistent result from different studies that
osteocalcin is depressed in patients with CS. In fact, this finding
is so reliable that it was even suggested to use osteocalcin in
the diagnosis of CS.(2) P1NP and procollagen carboxy-terminal
propeptide (P1CP) have also been studied in several studies, with
contradictory results.(23) In a retrospective study with 21 patients
with CS, it was shown that osteocalcin is depressed; this applies
also for PINP, whereas CTX is increased.(24)
Some studies already have focused on the reversibility of oste-
oporosis after treatment of CS. In the majority of patients, bone
mineral density increased within 2 years after successful
treatment(8–10,25) Hermus and colleagues showed in a study with
20 patients that bone mineral density did not change 3 or
6 months after surgery but increased thereafter in almost all
patients.(8) In a study with 68 patients, the patients were followed
up for 4 years. Bone mineral density increased over lumbar spine
and femur but decreased at the forearm.(25) The authors con-
cluded that bone minerals were redistributed from the periph-
eral to the axial skeleton.
In our study, bonemineral density also improved in themajor-
ity of patients but remained reduced in some. We did not find
any difference in bone turnover markers between patients with
improvement and without improvement.
Current treatment guidelines and treatment suggestions
As observed in our study, bone formation markers increase sig-
nificantly after surgical cure, whereas bone degradation markers
are mildly elevated at baseline and increase slightly at 1 year,
returning within the normal range at 2 years. So far, there is no
international guideline on the treatment of osteoporosis
induced by endogenous CS and very few controlled interven-
tional studies. In an opinion paper, Scillitani and colleagues
recommended to treat all patients with vitamin D and calcium
but not with bisphosphonates.(5) In a randomized open-label
study by Di Somma and colleagues,(26) 39 patients (18 patients
with active CS and 21 patients with CS in remission) received
alendronate or no medication. Patients with active CS also
received ketoconazole to control hypercortisolism. Bone mineral
density improved and serum levels of osteocalcin increased in
Table 3. Biochemical Markers in Patients With Cushing’s Syndrome With a T-Score Lower Than −1.5 and Above −1.5 Shown in Median
and Ranges
Variable T-score < −1.5 (n = 39) T-score ≥ −1.5 (n = 42) p Values
LDDST (μg/dL) 16.6. (10.3–28.3) 11.9 (6.1–21.9) 0.12
UFC (μg/24 h) 706 (410–906) 398 (285–787) 0.03
Late-night salivary cortisol (ng/mL) 8.3 (3.5–13.6) 5.7 (2.9–11.7) 0.39
ACTH (pg/mL) 53 (16–73) 42 (6–82) 0.88
LDDST = low-dose dexamethasone suppression test; UFC = urinary free cortisol; ACTH = adrenocorticotropic hormone. Bold numbers indicate statistical
significance.
Table 4. Bone Turnover Markers and Bone Mass in Patients With Cushing’s Syndrome at Time of Diagnosis and During 2 Years of
Follow-Up
Time of
diagnosis (n = 50)
1 year in
remission (n = 45)
2 years in







T-score −1.5 (−2.0 to −0.8) – −1.1 (−1.5 to −0.4) – <0.001 –
Osteocalcin
(ng/mL)
8 (5–13) 30 (14–60) 21 (13–31) <0.001 0.008 0.3
PINP (ng/mL) 35 (29–62) 117 (52–221) 69 (46–113) <0.001 0.1 0.1
BAP (μg/L) 23 (16–31) 26 (19–38) 22 (15–31) 0.2 0.4 0.1
CTX-I (ng/mL) 0.28 (0.17–0.42) 0.51 (0.22–0.91) 0.25 (0.18–0.73) 0.01 0.1 0.04
TrAcP (U/L) 2.3 (1.7–3.4) 2.8 (1.8–4.0) 2.3 (2–3.2) 0.1 0.6 0.002
PINP = procollagen I-N-propeptide; BAP = bone alkaline phosphatase; CTX-I = CrossLaps; TrAcP = tartrate-resistant acid phosphatase. Bold numbers indi-
cate statistical significance.
Table 2. Results of Multiple Linear Regression Analysis Compar-
ing Cushing’s Syndrome Patients Versus Controls
Dependent
variable
Standardized regression coefficient and p
value for group variable
Unadjusted










BAP (μg/L) 0.404, 0.001 0.470, <0.001
CTX-I (ng/mL) 0.111, 0.366 0.065, 0.616
TrAcP (U/L) 0.227, 0.014 0.186, 0.069
PINP = procollagen I-N-propeptide; BAP = bone alkaline phosphatase;
CTX-I = CrossLaps; TrAcP = tartrate-resistant acid phosphatase. Bold num-
bers indicate statistical significance.
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patients who received alendronate to a greater extent than
those receiving no alendronate.
In a small study by the same research group,(27) 15 patients
with CS (9 adolescent patients and 6 adults) were observed for
2 years after successful treatment, showing that osteocalcin
levels and bone mineral density increased significantly.
Strengths and limitations
Although this study has several strengths, including the large
prospective design and measuring a panel of bone formation
and resorptionmarkers, there are a few limitations. Some asymp-
tomatic fractures may have been overlooked because an X-ray
was not taken systematically in each patient. Furthermore, a
follow-up bone densitometry was not available for all patients.
Additionally, patients in the control group suffered from diabe-
tes, overweight, arterial hypertension, or other diseases.
Novel aspects and outlook
This study analyzes for the first time in a comprehensive way
bone turnover markers during the course of CS. The data show
that cure from CS leads to increases in bone remodeling and
bone mineral density, in line with spontaneous “bone healing.”
Our data support a wait-and-watch strategy despite a high
endogenous risk for additional fractures, based on the baseline
assessment. This observation will influence future therapeutic
strategies in patients with CS.
Our data suggest that the phase immediately after remission
from CS is characterized by a high rate of bone turnover, result-
ing in a spontaneous net increase in bone mineral density in
the majority of patients. Both bone attachment and bone degra-
dation markers increase significantly, leading to an increase in
bone mass and to a reduced risk of osteoporotic fractures. This
unconstrained increase in bone formation markers after remis-
sion should be considered before specific therapy is initiated.
Our data do not favor specific pharmacologic interventions with
bisphosphonates or denosumab during this phase of remodel-
ing because they may disrupt the osteoblast-mediated bone
mass increase.
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